Maze Therapeutics (MAZE) catalysts

Upcoming FDA decisions and readouts we track for Maze Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 11 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Maze Therapeutics (MAZE, listed on Nasdaq). They cover 2 programmes: MZE829 (APOL1-mediated kidney disease) and MZE782 (Phenylketonuria (PKU)).

First on the list: the Phase 2 readout for MZE829 (APOL1-mediated kidney disease), guided by the company to Late 2026. By stage, the upcoming rows are 2 Phase 2 readouts.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: MAZE
Next catalyst: Late 2026
Type: Phase 2 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Maze Therapeutics MAZE · Nasdaq	MZE829	APOL1-mediated kidney disease	Late 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states the company "expects to announce updated data in late 2026 or early 2027" across three 10-15 patient cohorts. Window spans a year end — treat the timing as soft. Source: 8-K exhibit 99.1, filed 11 Aug 2026 · verified 11 Sep 2026
Maze Therapeutics MAZE · Nasdaq	MZE782	Phenylketonuria (PKU)	2027 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Topline data from the trial is expected in 2027." Year-level guidance only. Source: 8-K exhibit 99.1, filed 11 Aug 2026 · verified 11 Sep 2026